Pathogenic role and therapeutic potential of fibro-adipogenic progenitors in muscle disease

Authors

Marshall W. Hogarth, Children's National Hospital, Center for Genetic Medicine Research, Washington, DC, USA. Electronic address: mhogarth@cnmc.org.
Prech Uapinyoying, Children's National Hospital, Center for Genetic Medicine Research, Washington, DC, USA; Neuromuscular and Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA.
Davi A. Mázala, Children's National Hospital, Center for Genetic Medicine Research, Washington, DC, USA; Department of Kinesiology, College of Health Professions, Towson University, Maryland, USA.
Jyoti K. Jaiswal, Children's National Hospital, Center for Genetic Medicine Research, Washington, DC, USA; Department of Genomics and Precision Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, USA. Electronic address: jkjaiswal@cnmc.org.

Document Type

Journal Article

Publication Date

1-1-2022

Journal

Trends in molecular medicine

Volume

28

Issue

1

DOI

10.1016/j.molmed.2021.10.003

Keywords

adipogenesis; fibrosis; injury; muscular dystrophy; osteogenesis; stromal cells

Abstract

Aside from myofibers, numerous mononucleated cells reside in the skeletal muscle. These include the mesenchymal cells called fibro-adipogenic progenitors (FAPs), that support muscle development and regeneration in adult muscles. Recent evidence shows that defects in FAP function contributes to chronic muscle diseases and targeting FAPs offers avenues for treating these diseases.

APA Citation

Hogarth, Marshall W.; Uapinyoying, Prech; Mázala, Davi A.; and Jaiswal, Jyoti K., "Pathogenic role and therapeutic potential of fibro-adipogenic progenitors in muscle disease" (2022). GW Authored Works. Paper 496.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/496

Department

Genomics and Precision Medicine